{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sahakyan Y"],"funding":["Canada Research Chair in the Economics of Infectious Diseases held by Beate Sander","CIHR","Canadian Institute of Health Research (CIHR)"],"pagination":["1224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11359558"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(8)"],"pubmed_abstract":["<h4>Background</h4>The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the \"HCV care-cascade\" is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the \"HCV care-cascade\" to achieve the WHO's HCV elimination targets in Ontario, Canada.<h4>Methods</h4>By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO's mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015).<h4>Results</h4>Without scaling up by 2030, the expected QALYs a"],"journal":["Viruses"],"pubmed_title":["Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada."],"pmcid":["PMC11359558"],"funding_grant_id":["FRN:201910MFE-430962-169632","CRC-950-232429","PJT-156066"],"pubmed_authors":["Sander B","Greenaway C","Wong WWL","Kwong JC","Janjua N","Sahakyan Y","Erman A"],"additional_accession":[]},"is_claimable":false,"name":"Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada.","description":"<h4>Background</h4>The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the \"HCV care-cascade\" is essential for meeting these targets. We aimed to identify the level of service scale-up needed along the \"HCV care-cascade\" to achieve the WHO's HCV elimination targets in Ontario, Canada.<h4>Methods</h4>By employing a decision analytic model, we projected the quality-adjusted life years (QALYs) and healthcare costs for individuals with HCV in Ontario. We increased RNA testing and treatment rates to 98%, followed by increasing antibody testing uptake until we achieved the WHO's mortality target (i.e., a 65% reduction in liver-related mortality by 2030 vs. 2015).<h4>Results</h4>Without scaling up by 2030, the expected QALYs a","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-04-22T03:13:15.722Z","creation":"2025-04-05T12:31:25.044Z"},"accession":"S-EPMC11359558","cross_references":{"pubmed":["39205198"],"doi":["10.3390/v16081224"]}}